Inhibition of the PI3K pathway as an anti-cancer therapeutic strategy was realized with the approval of the orally bioavailable small molecule PI3Kδ inhibitor idelalisib. In this focused review, we highlight the rationale for targeting the pathway in lymphomas, provide a brief summary of the preclinical data and describe the clinical experience with this agent in patients with lymphoma. We describe some of the idiosyncratic toxicities of this agent, mechanisms of resistance and some of the ongoing combination strategies.
Introduction
The phosphatidylinositol-3-kinase (PI3K) pathway plays an important role in multiple cellular functions including proliferation, differentiation and trafficking, and deregulation of PI3K is a hallmark of many malignancies, including hematologic cancers.
1 The PI3K p110δ isoform inhibitor, idelalisib (Zydelig, Gilead Sciences, Foster City, CA) was the first agent in a new class of isoform-specific inhibitors to receive regulatory approval. FDA approved indications for idelalisib include relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab in comorbid patients and relapsed follicular lymphoma (FL) with ≥ 2 prior therapies. The activity of idelalisib in CLL has been reviewed comprehensively elsewhere and will not be discussed further here.
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Rationale for targeting PI3K in lymphoma PI3K comprises a group of related enzymes that collectively regulate pleotropic downstream effector functions.
5 Class I PI3Ks are heterodimers comprising regulatory (p85) and catalytic (p110) subunits. The p110 subunit exists as four isoforms (α, 6 PI3Kδ appears critical to normal Bcell development, as PI3KCD knockout mice have defective antibody production, and kinase-dead mice develop inflammatory bowel disease. 7 The PI3K pathway is deregulated in a subset of cases in a variety of lymphoma subtypes including Hodgkin 8
, diffuse large B-cell 9 (DLBCL), mantle cell (MCL) 10 and FL. 11 Downstream effectors of PI3K signaling include the AKT/mTOR pathway, which governs oncogenic processes such as metabolism, chemoresistance, cell cycle regulation, growth and proliferation. 12 Whilst pan-PI3K inhibition as a therapeutic strategy is problematic owing to the ubiquitous expression of the α and β isoforms, inhibition of delta isoform-specific PI3K signaling is an attractive target in lymphoid malignancies.
Preclinical data
Idelalisib is an orally available, highly selective PI3Kδ small molecule inhibitor identified in kinome-wide screening assays. The IC 50 for the p110δ catalytic subunit of PI3K is 2.5nM, at least 40-to 300-fold more potent than other PI3K isoforms. 13 Furthermore, a 401 kinase screening assay at 10nM did not identify significant off target activity. 13 In initial experiments performed at Ohio State University, idelalisib induced caspase dependent death of malignant CLL cells, suppressed pro-tumor cytokine production by T-and NK-cells and abrogated pro-survival microenvironmental signals such as BAFF, TNFα and fibronectin. 14 Using both patient-derived samples and cell lines, Lannutti et al showed preferential in vitro activity of idelalisib in B-cell malignancies resulting from inhibition of constitutively activated PI3K signaling, ultimately resulting in decreased Akt phosphorylation and apoptosis. 13 Hoellenreigel et al showed that idelalisib blocks nurse-like cell and B-cell receptor derived survival signals, reduces secretion of chemokines CCL3, CCL4 and CXCL13, and sensitizes CLL cells to cytotoxic agents. 15 These important preclinical investigations corresponded with observed changes in CLL patients' cytokine levels
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From and subsequent trafficking of malignant lymphocytes out of bone marrow and nodal sites into the peripheral blood. 15 The potential mechanisms of action of idelalisib are summarized in Figure 1 . These studies highlight the pleotropic cellular effects of idelalisib and have provided rationale for clinical development, both as a single agent and in combination with other biologic agents and conventional cytotoxics.
Clinical data

Pharmacokinetics and pharmacodynamics
Idelalisib displays linear pharmacokinetics and biotransformation occurs primarily through the action of aldehyde oxidase; secondary metabolic pathways include cytochrome P4503A and glucuronidation. 16 Concomitant use of the CYP3A inducers reduce idelalisib exposure and should be avoided. 17 CYP3A inhibitors and moderatesevere renal or hepatic impairment increase idelalisib exposure but do not necessitate dose modification, however careful monitoring for toxicity is recommended. 17 Data regarding the distribution of idelalisib into non-plasma compartments, such as cerebrospinal fluid, are unavailable at the time of writing.
Phase I/II studies
An overview of clinical trials involving idelalisib as a single agent in NHL is presented in Table 1 . The phase Ia study in healthy volunteers established both oral bioavailability and confirmed that drug levels were achievable in the plasma at levels shown to achieve pharmacologic inhibition of PI3K. 18 The phase Ib study included patients with relapsed/refractory hematologic malignancies; from this, Flinn et al reported the outcomes of 64 patients with relapsed/refractory indolent B-NHL, 38 (59%) with FL, 11 (17%) with small lymphocytic lymphoma (SLL), 9 (14%) with lymphoplasmacytic lymphoma (LPL) and 6 (9%) with marginal zone lymphoma (MZL). 16 Patients had a median age of 64 years and 4 prior therapies, with 37 (58%) refractory to the immediately preceding line of therapy. A variety of different dosing schedules were explored, including from 50mg daily to 350mg twice daily, 150mg to 300mg once daily, and 3 weeks on, 1 week off. Interestingly, exposure to idelalisib did not result in a change in serum immunoglobulin levels or a change in T-helper, cytotoxic T-cell or NK-cell numbers. Responses were observed across histologic subtypes: among response evaluable patients, 85% experienced reduction in lymphadenopathy, with an objective response rate (ORR) across all dose levels of 48% (complete response [CR] 2%) after a median of 1.3 months. The median duration of response (DOR) was 18.4 months (range 0.03 -34). Both ORR (59% vs 37%) and median progression free survival (PFS) (16.8 vs 3.7 months) was greater among patients treated continuously at dose levels ≥ 150mg twice daily. Considering dose-exposure data, 150mg twice daily was selected as the recommended phase II dose.
On the basis of these data Gopal et al performed an international multi-center phase II study in rituximab and alkylator-refractory indolent B-cell lymphomas DELTA) . 19 This registration study enrolled 125 patients at centers across North America and Europe who were treated with idelalisib 150mg twice daily until disease progression, unacceptable toxicity or death. The median age of patients was 64
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From years (range 33 -87), their histologic subtypes included FL (n=72, 58%), SLL (n=28, 22%), MZL (n=15, 12%) and LPL (n=10, 8%) and they were heavily pre-treated, with a median of 4 prior lines of therapy (range 2 -12). Ninety percent were refractory to the immediately preceding line of therapy. Despite this, significant anti-tumor activity was observed, with 90% of patients experiencing tumor reduction. An independent review committee determined the ORR to be 57% (CR 7%), with no significant differences observed between pre-defined subgroups. After a median follow-up of 9.7 months, the median PFS and overall survival (OS) were estimated at 11.0 months (range 0.03 -16.6) and 20.3 months (range 0.7 -22.0) respectively. A >3-fold increase in absolute lymphocyte from baseline occurred in 7/11 (64%) patients with SLL, 7/38 (18%) with FL, 1/6 (16% with MZL) and 0/9 patients with LPL. In a subset analysis of 37 patients from the phase II study with FL and early disease progression (defined as EFS ≤ 24 months after frontline chemo-immunotherapy), idelalisib retained significant activity (ORR 57%, CR 13%) with a median PFS 11.1 months. 20 A recent pooled subgroup analysis included patients with MZL from the phase Ib (101-02, n=6) and phase II (101-09, n=15) studies. The MZL subtypes included mucosal associated lymphoid tissue lymphoma (n=12), nodal MZL (n=7) and splenic MZL (n=2). The ORR in the two studies was 2/6 (33%) and 7/15 (47%) with median PFS of 7.4 and 6.6 months respectively.
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Given the importance of the PI3K/Akt/mTOR pathway in pathogenesis, 22,23 exploring the activity of idelalisib in mantle cell lymphoma (MCL) was logical. Kahl et al reported the results from 40 patients with relapsed/refractory MCL treated on the phase Ib study. 24 The study population included many heavily pre-treated (median number of prior therapies 4 [range 1-14]) patients, but excluded ibrutinib-exposed patients. The dose ranges explored were identical to those used in indolent NHL. The ORR across all doses was 40% (CR 2%). Patients treated at the phase II dose or higher were more likely to respond than those treated at lower doses (ORR 69 v 21%). The median DOR and PFS were 2.7 and 3.7 months respectively, with a trend toward longer PFS among less heavily pre-treated patients (mPFS 8.2 vs 3.7 months, dichotomized at 6 prior therapies). In particular, 8/40 (22%) experienced clinical benefit exceeding 12 months. Treatment-emergent lymphocytosis was rare relative to patients with CLL/SLL; 5 (12%) experienced >3-fold elevation in absolute lymphocyte count relative to baseline. The limited duration of response in patients with MCL suggest the rapid development of resistance to p110δ inhibition.
Toxicity
The toxicities caused by this agent merit further discussion. The most common adverse events (AEs) reported in the phase Ib and II studies were fatigue, diarrhea, nausea, rash, chills and pyrexia, while the most frequent grade≥3 AEs were diarrhea and pneumonitis. 16, 19 Grade ≥ 3 elevation of serum transaminases occurred in 16 (25%) of patients. Although reversible in most cases, up to a quarter experience recurrent elevation on re-challenge. 25 Careful monitoring of liver function tests during treatment and avoidance of concomitant hepatotoxic medications is therefore advised. Grade≥3 neutropenia occurred in 16 (25%) although no relationship with dose level was evident. The median time to onset of grade≥3 elevation in transaminases was 5.3 weeks. In all instances, transamanitis resolved to grade 1 after a median of 3 weeks. Diarrhea was common, with two patterns apparent: within the first 8 weeks, a milder form responsive to anti-motility agents, and a more severe form that occur later and is not. Grade ≥ 3 diarrhea (defined as >7 stools/day above baseline) have been observed in ~14% of patients on reported clinical trials. 16, 24, 26, 27 In anecdotal reports, oral budesonide appears to shorten symptoms. 25 Intestinal perforation was rare and occurred in <1% patients treated. Pneumonitis was reported in 3% of patients treated on single agent studies, and was rarely fatal (<0.5%). 19, 24, 28 Pneumonitis generally occurred after several months of treatment (median of 7.8 months) and typically presented with cough, dyspnea, and fever with ground-glass opacities noted on computed tomography of the chest.
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Unexpected and severe toxicity in idelalisib combination studies
Given the success of idelalisib as monotherapy, attempts have been made to combine it with other agents. Idelalisib has been combined with the anti-CD20 monoclonal antibodies rituximab in patients with chronic lymphocytic leukemia without significant increases in toxicity apartment from increased rates of grade≥3 neutropenia (34 vs 22%). 26 The triplet of lenalidomide, idelalisib and rituximab caused serious toxicity, resulting in the closure of three early phase studies. 
Opportunistic infections halt phase III studies
Recent data indicate idelalisib combinations cause immune deficiency in addition to autoimmune toxicity. A recent safety analysis of 3 phase III studies in subjects with previously untreated CLL (bendamustine/rituximab [BR] ± idelalisib) and previously treated indolent B-cell NHL (rituximab ± idelalisib and BR ± idelalisib) were recently halted due to an excess of deaths and serious adverse events among patients treated on the idelalisib-containing arms (combined mortality rate 49/664 (7.4%) vs 12/402 (3.5%).
37 These were largely attributable to increased opportunistic infections, notably Pneumocystis jirovecii pneumonia (PJP) and cytomegalovirus (CMV) reactivation. Among the 20% of patients in whom PJP prophylaxis was administered, no deaths occurred. An increased risk of opportunistic infections has previously been reported among patients treated with bendamustine-containing regimens.
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Nonetheless, due to the apparent increase in risk, we have modified our practice to include mandatory PJP prophylaxis with trimethoprim-sulfamethoxazole. 41 Patients on idelalisib presenting with fever, hypoxia and pulmonary infiltrates should discontinue idelalisib and be treated empirically until Pneumocystis jirovecii can be excluded. If non-infectious pneumonitis is suspected prednisone should be continued. Prior to commencing idelalisib, all patients should have CMV status assessed. CMV seronegative patients should receive CMV negative or filtered blood products. For seropositive patients, we have extrapolated from alemtuzumab guidelines 42 and perform regular (e.g. monthly) CMV antigen or quantitative PCR testing. Idelalisib should be discontinued and ganciclovir or valganciclovir preemptively initiated in patients with positive CMV PCR/antigen and symptoms consistent with CMV infection, patients presenting with fever and no clear source in whom quantitative CMV testing is unavailable, and in asymptomatic patients with increasing viral load. We have provided a summary of recommendations for the management of toxicity associated with idelalisib, incorporating our synthesis of the US prescribing information, 43 expert consensus guidelines 25 and recommendations arising from the recent safety warning 37 in Table 2 . Although the increased risk of opportunistic infection appears to result in patients treated with idelalisib and rituximab ± bendamustine, until further safety data are available, the suggestions regarding PJP prophylaxis and CMV monitoring should be considered for all patients treated with the agent.
Mechanisms of resistance
At this point limited data are available regarding the mechanisms of resistance to idelalisib. Iyengar et al studied PI3K class IA isoforms in primary patient MCL samples and demonstrated that while p110δ was widely overexpressed, p110α expression was variable, and significant increases occurred with disease progression. 44 Further, they noted that while PI3Kδ inhibition was sufficient to abrogate B-cell receptor mediated PI3K signaling, switching off constitutive activation of PI3K required blockade of both PI3Kα and PI3Kδ. Whole exome sequencing identified PI3KCA gain-of-function mutations (N345K, P539R, E970K) in 3 independently generated idelalisib resistant WSU-Fccl FL cell line clones and compensatory activation in SFK and WNT pathways were documented. 45 In an idelalisib-resistant ABC DLBCL cell line, loss of PTEN protein expression, modest is a bifunctional molecule engineered to incorporate hydroxamic acid into a PI3K inhibitory structure, thus targeting both class I PI3K and class I/II histone deacetylase (HDAC) enzymes with one molecule. 53 In the phase I study responses were observed in 6/11 (55%) response-evaluable patients with diffuse large B-cell lymphoma (DLBCL).
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Conclusion
Idelalisib provides an important option for patients with relapsed/refractory indolent B-cell lymphoma. Although most adverse events are manageable, careful monitoring for opportunistic infections such as PJP and CMV reactivation, and immune toxicities including elevation of serum transaminases, colitis and pneumonitis is necessary. Some of these adverse events may be more prevalent in the frontline setting, and are exacerbated when combined with other immunostimulatory biologic agents. Careful design and conduct of studies will define the optimal combinations and populations most likely to derive benefit (and experience unacceptable toxicity) from this important new therapy. 
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